San Diego, CA (Press Release) – Fortis Therapeutics, Inc., an immuno-oncology bio­tech devel­op­ing a novel anti­body-drug con­ju­gate (ADC) against CD46, today announced the U.S. Food and Drug Admin­istra­tion (FDA) has cleared two inves­ti­ga­tional new drug (IND) appli­ca­tions for the com­pany’s lead can­di­date, FOR46, for the treat­ment of metastatic castration-resistant prostate cancer and late-stage multiple myeloma. The Phase 1 trial of FOR46 in metastatic castration-resistant prostate cancer is planned to launch by the end of the year. The second pro­gram, in late-stage multiple myeloma, is ex­pec­ted to move into clin­i­cal trials in early …